HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. Blood 2006 Feb 01;107(3):1220-6
Date
10/20/2005Pubmed ID
16234356DOI
10.1182/blood-2005-08-3121Scopus ID
2-s2.0-31544468676 (requires institutional sign-in at Scopus site) 91 CitationsAbstract
Studies in unrelated donor (UD) hematopoietic stem cell transplantations (HSCT) show an effect of the matching status of HLA-DPB1 on complications. We analyzed 423 UD-HSCT pairs. Most protocols included T-cell depletion (TCD). All pairs had high-resolution tissue typing performed for 6 HLA loci. Two hundred eighty-two pairs were matched at 10 of 10 alleles (29% were DPB1 matched). In 141 HLA-mismatched pairs, 28% were matched for DPB1. In the 10 of 10 matched pairs (n = 282), the 3-year probability of relapse was 61%. This was significantly higher in DPB1-matched pairs (74%) as compared with DPB1-mismatched pairs (56%) (log rank, P = .001). This finding persisted in multivariate analysis. In the group overall (n = 423), relapse was also significantly increased if DPB1 was matched (log rank; P < .001). These results were similar in chronic myeloid leukemia (CML; P < .001) and acute lymphoblastic leukemia (ALL; P = .013). In ALL, DPB1-matched pairs had a significantly worse overall survival (log rank; P = .025). Thus, in recipients of TCD UD-HSCT, a match for DPB1 is associated with a significantly increased risk of disease relapse, irrespective of the matching status for the other HLA molecules. It is possible that this effect is especially apparent following TCD transplantations and invites speculation about the function of DPB1 within the immune system.
Author List
Shaw BE, Marsh SG, Mayor NP, Russell NH, Madrigal JAAuthor
Bronwen E. Shaw MBChB, PhD Center Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Aged
Child
Child, Preschool
Disease-Free Survival
Female
HLA-DP Antigens
HLA-DP beta-Chains
Hematopoietic Stem Cell Transplantation
Histocompatibility Testing
Humans
Infant
Leukemia
Lymphocyte Depletion
Male
Middle Aged
Recurrence
Risk Factors
Tissue Donors
